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INTRODUCTION
The 2012 ST-segment elevation acute myo-
cardial infarction (STEMI) guidelines of the 
European Society of Cardiology (ESC) state 
that: “Routine [manual] thrombus aspiration 
should be considered in STEMI” (Class IIa, 
level of evidence B) [1].
Consideration of manual thrombus aspiration (TA) is 
therefore an important part of routine interventional manage-
ment of STEMI patients [2, 3]. 
The 2013 ESC Congress presentation of the Thrombus 
Aspiration in ST-Elevation myocardial infarction in Scandinavia 
(TASTE) study outcome that 30-day all-cause mortality (the 
primary endpoint) was not significantly affected by manual 
TA in STEMI [4, 5] made prominent headlines through the 
ESC press release and internet cardiology services. These 
headlines indicated that: “TASTE questions the usefulness of 
thrombus aspiration as a routine adjunct [to primary PCI]” [4], 
“Thrombectomy a letdown for PCI-treated STEMI patients” 
[6], and “International STEMI guidelines should probably be 
down-graded” [4]. Indeed, the official ESC news release of 
1 September 2013 indicated that: “The [TASTE] study results 
will likely have an immediate impact on clinical practice” [4]. 
Even before the TASTE data surfaced, the Heartwire voiced 
that: “TASTE most likely will dictate future guidelines” [7]. 
As today’s physicians (including cardiologists) are becom-
ing increasingly reliant on internet delivery of ‘digested’ re-
search data [4, 6, 7], a fundamental question that needs to be 
addressed in the light of TASTE publication and its sensational 
coverage by cardiology news services is the following: Should 
we indeed, after TASTE, stop our routine consideration of 
manual thrombus aspiration in STEMI patients? 
Rather than a remote academic question, this is an im-
portant practical issue that may affect the long-term clinical 
outcome of today’s STEMI patients [2, 8]. Following the TASTE 
publication [5] and its sensational coverage [4, 6, 7], in the 
last quarter of 2013 some primary percutaneous coronary 
intervention (pPCI) operators have already started abandon-
ing their habit of routine consideration of thrombus aspiration 
in STEMI. Some others, overwhelmed by the information 
noise [4, 6, 7], are not sure whether they should stick to the 
guideline-indicated management and consider offering TA to 
their patients any longer because the “guidelines are likely to 
be down-graded” [4].
Is there really any evidence today that allows the pPCI 
operator to deliberately fragmentise the clot and send it (parts 
of it) down to obstruct coronary microcirculation in a STEMI 
patient — rather than remove the clot (or at least part of it) 
from the infarct-related artery (IRA) prior to inserting a balloon 
or implanting, directly, a stent? 
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MOST CULPRIT LESIONS  
IN IRA ARE THROMBOTIC:  
SOMETHING NEEDS TO ‘HAPPEN’  
WITH THE THROMBUS DURING PRIMARY PCI
Intracoronary thrombosis, resulting from atherosclerotic 
plaque rupture or erosion, is the leading mechanism of acute 
coronary syndromes (ACS) [1, 2, 8]. Angiographic thrombus 
presence and its size are important determinants of the risk of 
distal macro- and microembolisation and myocardial damage 
[2, 8]. Stent-assisted pPCI plays a central role in achieving 
rapid and effective opening of the IRA and elimination of 
the flow-limiting lesion. Evidence shows a strong association 
between the presence of IRA thrombus and an increase in 
myocardial injury with pPCI, leading to adverse clinical out-
comes, with the thrombus size being an important negative 
prognostic marker [2, 8]. It is well-known today that the goal 
of successful reperfusion strategies in ACS is microcirculatory 
myocardial perfusion and myocardial salvage rather than ‘just’ 
flow re-institution in the IRA [1, 2, 8]. 
More than a decade ago, the TIMI Group established 
that myocardial reperfusion resulting in an open microvascu-
lature (manifest as TIMI myocardial perfusion grade [TMPG] 
2 or 3) was associated with significantly lower mortality at 
two years than TMPG 0 or 1 (4.76% vs. 9.07%, p = 0.038) 
[9]. Consistently, landmark findings from the Cardiovascular 
Research Foundation investigators demonstrated that in pa-
tients in whom epicardial TIMI-3 flow was restored, survival 
was strongly dependent on the post-angioplasty myocardial 
perfusion, with one-year cumulative mortality of 6.8% with 
normal myocardial perfusion, 13.2% with reduced myocar-
dial perfusion, and 18.3% in patients with absence of effec-
tive myocardial perfusion (p = 0.004, epicardial IRA flow 
TIMI-3 in all) [10]. Effective myocardial tissue reperfusion is 
thus established as a key determinant of left ventricular func-
tion and long-term (N.B. not: short-term) survival after ACS [2].
IRA thrombus, a major determinant of poor myocardial 
tissue reperfusion in ACS and a poor long-term clinical out-
come, is managed in a pharmacological, a mechanical, or 
a combined, way [2, 8].
THROMBUS MANAGEMENT CHOICES:  
REMOVE, DISSOLVE, TRAP AT THE LESION SITE 
— OR FRAGMENTISE AND SEND DOWN  
TO OBSTRUCT MICROCIRCULATION 
Pharmacologic total thrombus resolution is rare in the ab-
sence of fibrinolytic treatment (the latter being associated 
with a clinically-relevant risk of bleeding complications) [2]. 
Data prior to the era of routine TA provided evidence that 
an adverse long-term clinical outcome of pPCI is determined 
by the magnitude of microcirculatory flow deterioration that 
occurs with optimisation of stent expansion in a thrombotic 
lesion through the ‘cheese-grater’ effect [2, 11]. This led to 
the concept that thrombus extraction from IRA, as a means 
to reduce distal vasculature obstruction and myocardial dam-
age, may improve the long-term outcome of pPCI [2, 8, 12].
Multi-centre evidence indicates that manual thrombus 
extraction through an aspiration catheter, adopted either as 
a routine strategy or targeted to patients with angiographic 
evidence of thrombus, leads to improved myocardial perfu-
sion and a reduced infarct size [2, 13–15]. There are theo-
retical grounds and clinical data that pharmacological and 
mechanical thrombus burden reduction act synergistically to 
obtain the best myocardial reperfusion and, in consequence, 
the best clinical outcome [2, 8]. Pharmacological reduction of 
thrombus burden is most effective in ACS patients presenting 
early after symptom onset [1, 2, 16]. Recent data confirm 
that a strategy that combines manual thrombus extraction 
with lesion-directed pharmacotherapy translates into max-
imised infarct size reduction [16]. The INFUSE-AMI trial, 
using 2 × 2 factorial design in 452 patients presenting with 
a large anterior myocardial infarction within 4 h of symptom 
onset (i.e. early presenters) showed that the infarct size by 
cardiovascular magnetic resonance imaging (cMRI) was small-
est when manual thrombus aspiration was combined with 
abciximab infusion directly at the lesion site via a ‘weeping’ 
balloon (median infarct size of 14.7% vs. 17.6%, p = 0.03, 
comparison of TA + intracoronary abciximab vs. a combined 
group of no TA/no abciximab + TA/no abciximab + no TA/no 
abciximab) [16]. 
The optimal treatment of patients with a thrombus-con-
taining lesion needs to integrate pharmacologic and mechani-
cal approaches to thrombus burden reduction to minimise 
its impact on myocardial (tissue) reperfusion [2, 8]. Other 
concepts to reduce the impact of thrombus burden on myo-
cardial loss, discussed in more detail elsewhere [2], include 
the application of mesh-covered stents to trap the embolic 
material; the use of these, however, is limited to (for instance) 
non-bifurcated lesions [2].
MYOCARDIAL SALVAGE WITH THROMBUS  
ExTRACTION: THE ESTABLISHED SHORT-TERM 
VS. LONG-TERM ENDPOINTS
Key randomised studies of manual TA, [13–15], registries [17] 
and meta-analyses [18–21], have consistently demonstrated 
that TA prior to stent implantation (or balloon use) in pPCI 
improves short-term indices of myocardial salvage such as 
angiographic measures of myocardial reperfusion (TMPG or 
myocardial blush grade) or ST segment resolution, and the to-
tal infarct size or the size of microvascular obstruction on cMRI 
[2, 13–21]. In contrast, these studies (and their meta-analyses) 
have consistently demonstrated that the clinical benefit of TA 
(mortality reduction or reduction in clinically-significant heart 
failure [HF]) manifests not earlier than 12 months after the 
index event [18–21].
An increase in time to treatment in STEMI is a major pre-
dictor of impaired myocardial reperfusion despite a successful 
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restoration of the epicardial (IRA) flow [1]. The INFUSE-AMI 
findings suggest that STEMI patients with short presentation 
(within 4 h of symptom onset) may receive relatively less bene-
fit from TA when local (intra-lesional) abciximab influsion is on 
board [16] as the ‘early’ thrombus is known to be particularly 
prone to pharmacological management [1, 2]. On the other 
hand, recent pooled analysis of individual patient data of three 
prospective randomised trials of manual TA in STEMI showed 
that TA can attenuate the adverse effect of time-to-treatment 
prolongation on myocardial reperfusion [22]. 
In most TA studies and their meta-analyses to-date, TA 
did not affect the short-term outcome of 30-day mortality in 
STEMI [13, 17–20]. Nevertheless, long-term data — such as 
that from INFUSE-AMI — shows that, even in patients with 
early cathlab presentation in ACS, TA compared to no aspira-
tion was associated with lower rates of new-onset severe HF 
(0.9% vs. 4.5%; p = 0.02) and of re-hospitalisation for HF by 
one year (0.9% vs. 5.4%; p = 0.0008) [23]. This is not surpris-
ing, because it has been known for a long time that the effect 
of improved reperfusion on clinical outcome may not become 
apparent until one–two years after the index ischaemic event 
[9, 10]. In contrast to the (expected) lack of effect of TA on 
30-day mortality, the evidence to date is internally consistent 
in demonstrating a reduction in 12-month mortality with TA 
in STEMI [12, 14, 17, 18, 21]. 
Thus a consistent body of evidence indicates that the 
short-term (such as 30-day) effectiveness of TA is reflected 
by myocardial perfusion and infarct size parameters. In con-
trast, the clinical effect of TA, as manifested by a reduction 
in new-onset HF and HF hospitalisations or mortality reduc-
tion, does not become detectable until some 12 months 
after STEMI.
TASTE SHOWS DISSOCIATION BETWEEN  
THE STUDY HYPOTHESIS  
AND CHOICE OF THE ENDPOINT 
When evaluating the applicability of a study to clinical prac-
tice, two fundamental questions need to be addressed: (i) is 
this study aim/hypothesis valid?; and (ii) do the findings from 
the study support the hypothesis? (N.B. the third question 
is whether the findings are applicable to a particular (‘my’) 
patient) [2, 3].
TASTE was conducted to test the hypothesis that manual 
TA, as an adjunct to standard PCI, “confers a better outcome 
compared to PCI alone in patients with STEMI” [24]. The 
TASTE study was undertaken because, in view of its Investiga-
tors, “additional evidence needed to be established” [24] since 
“thrombus aspiration [in STEMI] either saves lives or is a killer, 
we don’t know” [7]. To test the hypothesis of a potentially 
better outcome with TA in STEMI patients, TASTE selected the 
primary endpoint of all-cause mortality at 30 days [5, 24]. Here 
comes the principal problem with TASTE: its choice of 30-day 
mortality as the study endpoint [5, 24] is against the wealth of 
published evidence (in an overall patient population similar 
to that in TASTE) that TA is highly unlikely to affect 30-day 
mortality [13, 14, 17, 18]. No explanation for this unfounded 
early mortality primary endpoint choice has been provided 
[5, 24]. It is also surprising that the TASTE power calculations 
[5, 24] were based on the 30-day mortality in the TAPAS study 
in which (in contrast to the significant 12-month mortality 
reduction in a study of 1,071 STEMI patients [12]), the 30-day 
mortality was unaffected by manual TA [13]. Moreover, the 
seemingly firm conclusion from TASTE is based, in fact, on 
only half of the originally scheduled events in this study [5, 24].
Thus the principal hypothesis of TASTE, that the reduction 
in myocardial injury/infarct size with TA (if it occurred) would 
be large enough to affect mortality ‘already’ at 30 days is not 
founded by pathophysiology or data from other studies. The 
totality of pre-TASTE evidence (in an overall group of ca. 
4,000 patients) [13, 14, 17, 18] shows that, in present patient 
populations, the endpoint of early (such as 30-day) mortality 
is highly unlikely to be sensitive enough as the demonstration 
of clinical effect of TA on myocardial salvage. 
In essence, while undertaking a study that aims to 
evaluate whether manual TA reduces mortality is (with Ethics 
Committee approval) acceptable for investigators who do 
not find the totality of prior evidence sufficient, the choice 
of 30-day mortality as the primary study endpoint of a TA 
study is unfounded. 
TASTE: MISSING ROUTINE BIOMARKER INFARCT 
SIZE AND ST-SEGMENT RESOLUTION DATA
With the scheduled study population of 5,000 STEMI pa-
tients [24] and 7,244 actually randomised [5], TASTE had the 
potential to detect an effect TA on, for instance, ST segment 
resolution and biomarker infarct size reduction. In view of the 
effect on these routine short-term endpoints in prior studies 
of manual TA in STEMI [13, 17, 18, 20], it is unclear why the 
TASTE protocol, focused on a short-term outcome [5], did not 
include ST segment resolution at (for instance) 90 min after 
reperfusion. It is also unclear why routinely available infarct 
size data (e.g. peak CK-MB or peak troponin value that is 
known to correlate with infarct size on MRI [2, 25]) were not 
collected in TASTE. These could have served as important 
secondary endpoints.
Unfortunately, the impact of TA on routine short-term 
indices of myocardial salvage remains, in the TASTE study, 
unknown, and it is unclear why this important data was 
not captured.
SOME OTHER ISSUES WITH TASTE  
— SUCH AS ExCLUSION OF PATIENTS IN WHOM 
THROMBUS ASPIRATION WAS CONSIDERED  
TO BE INDICATED
There is no doubt that TASTE Investigators are to be com-
mended for their pioneering concept of a randomised trial 
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within a national registry [24], and the effort they have made 
to gather and analyse data from a large patient population, 
including data capture in those not randomised. While 
long-term clinical results from TASTE are awaited (i.e. the 
endpoints that TA, in light of prior evidence, might actually 
have an effect on [12, 14, 17, 18, 21]), several points other 
than the unfounded choice of 30-day mortality as a primary 
TASTE endpoint need to be made. 
In TASTE, 40% of patients presenting with STEMI and 
referred to pPCI were excluded from randomisation [5]. The 
principle of randomisation is uncertainty to the treatment 
effect [2], and randomisation in TASTE was performed after 
obtaining the angiogram [5, 24]. Therefore one would expect 
that at least some TASTE operators would have decided, on 
a purely ethical basis, to exclude from randomisation patients 
with a substantial thrombus burden in their IRA. Is there any 
evidence that this subject selection bias did actually occur?
The TASTE publication indicates clearly that when TA 
was considered indicated it was performed, and the patient 
was not part of the randomised study [5]. Thus the patients 
who were considered to benefit most from TA became, 
paradoxically, removed from the study of the effect of TA in 
STEMI [5]. While this is certainly right in terms of ethics, such 
a study is no longer able to test the effect of TA in a “STEMI 
population”. Therefore what TASTE, in fact, tested was the 
effect of TA in patients in whom TA was not considered to 
be indicated, with an obvious impact of this patient selec-
tion bias also on the long-term study endpoints. Lack of an 
appropriate statement (with an appropriate weight — such 
as in the title or abstract) confuses the recipient of the study 
message. Large patient numbers cannot (and thus will not) 
make up for the (possible) design and (definite) study data 
communication flaws. 
The TASTE data shows that among those non-ran-
domised to TASTE (n = 4,697), TA was actually performed 
in 1,162 (25%) patients, including those in whom TA was 
a priori considered to be indicated [5]. This calls for at least 
an additional per-treatment analysis of outcomes including 
those patients in whom TA was a priori considered to be 
indicated. This bias is likely to be significant because TASTE 
(although it claims that its “patients were treated according to 
international guidelines” [5]) did continue to recruit patients 
after publication of the 2012 ESC STEMI guidelines (October 
2012) where TA consideration is a class IIa recommendation. 
In fact, 2,442 (33.7%) TASTE patients were recruited after the 
interim data analysis that occurred in August 2012 [5]. 
TASTE data has not been centrally adjudicated. It is un-
clear why a very large proportion of non-randomised STEMI 
patients (38%) [5] were the patients flagged as “unable to 
provide informed oral consent” to undergo randomisation to 
TA–assisted pPCI vs. pPCI without TA. This ‘main’ flag is likely 
to hide a proportion of non-randomised patients in whom TA 
was actually performed [5].
Another important limitation of TASTE is that its proto-
col restricted TA to the use of 6 F aspiration catheters while 
the aspiration capacity of 7 F catheter is known to be ≈50% 
higher than that of a 6 F aspiration catheter [2, 3]. This limita-
tion goes against the current practice of TA with the use of 
7 F catheters in larger arteries and larger thrombus burdens 
[2, 3] (examples in Figs. 1, 2) and it might have significantly 
confounded TASTE data by leading to suboptimal thrombus 
extraction in patients with large arteries and large thrombus 
burden (i.e. those likely to gain most benefit from thrombus 
extraction) [2, 3].
POST-TASTE LANDSCAPE: NO EVIDENCE  
TO CHANGE THE CURRENT PRACTICE
A large body of consistent data shows, in aggregate, that TA 
in STEMI patients is associated with an improved myocardial 
perfusion and reduced infarct size while the clinical benefit 
of TA (manifest as a reduction in new onset HF, reduction in 
HF hospitalisations, or reduction in mortality) does not occur 
until 12–24 months after the index ACS [12, 14, 17, 18, 21].
TASTE, a randomised registry trial [24], aimed to evaluate 
the hypothesis that TA “confers a better outcome” compared 
to PCI alone [5, 24]. This hypothesis was tested by assessing 
30-day mortality as the primary endpoint of the study; the 
endpoint known not to be affected by TA in prior studies and 
their meta-analyses [13, 14, 17, 18].
Importantly, TASTE excluded from randomisation patients 
in whom TA was considered to be indicated [5], and TA was 
performed in 25% of those excluded from randomisation 
[5]. Routine exclusion, from a study of TA, of the patients ex-
pected to benefit from TA, is likely to affect also the long-term 
outcome from the study. Irrespective of whether this patient 
proportion is 10% or 25%, these are likely to be the patients 
who might have driven the outcome of the study. Therefore, 
even if future 12-months TASTE data shows no apparent ef-
fect of mortality, this will not form any evidence that TA is not 
overall effective in today’s STEMI patients. 
What TASTE demonstrated is that, in the randomised pa-
tients (i.e. having excluded those in whom TA was considered 
to be indicated), the 30-day mortality was not significantly 
affected by TA (2.8% TA vs. 3.0% PCI-only group; p = 0.63) 
[5]. This finding is not unexpected as it is entirely consistent 
with prior evidence that myocardial salvage with TA translated 
into reduction of long-term clinical endpoints (including mor-
tality) but not of 30-day mortality [13, 17, 18, 24]. For these 
reasons, TASTE provides no grounds to change the current 
(evidence-based and guideline-indicated) strategy of routine 
TA consideration in STEMI patients [1].
It needs to be noted that manual TA is not the manage-
ment for all STEMI patients and all culprit lesions in STEMI; 
several limitations to its use are discussed elsewhere [2, 3]. It is 
also known that, in inexperienced hands in particular, TA can 
be associated with an increased risk of coronary and extracar-
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Figure 1. Coronary thrombus extraction in current state-of-the-art management of a STEMI patient. A 45-year-old man was 
admitted following 20-min severe retrosternal pain and ventricular fibrillation on paramedics’ arrival. Cathlab direct admission 
ECG (A) was consistent with anterior STEMI, and coronary angiogram demonstrated left anterior descending coronary artery 
abrupt occlusion (B, white arrow; N.B. the right coronary artery was normal and is not shown). The patient was loaded orally 
with prasugrel (initial intravenous heparin and oral aspirin had been given by the paramedics). In the operator’s judgment, the 
clinical presentation and image in B were consistent with a thrombotic occlusion of the IRA; thus thrombus extraction was 
performed with a 7 F Export aspiration catheter whose aspiration capacity is ≈50% higher than that of a 6 F aspiration cathe-
ter [2, 3] (C, white arrow indicates the marker at the tip of aspiration catheter, D shows the thrombi extracted from IRA in this 
patient). With thrombus extraction (considered by the operator, in this scenario, routine) the IRA flow was re-established (E). This 
enabled direct stenting, which was performed with a bioabsorbable sirolimus-eluting Absorb 3.5 × 12 mm scaffold implanted at 
4–12 atm over 70 s and post-dilated with a non-compliant 3.5 × 9 mm balloon at 16 atm (image F was taken immediately after 
the stent-implantation balloon deflation, black arrows point to the platinum markers of the stent which itself, made of poly-L-
-lactide, is completely invisible on angiogram; the external markers along the angioplasty wire are the deflated balloon markers). 
Final angiographic result is shown in G (arrows indicate the position of the stent that will undergo complete biodegradation 
over ≈2 years; vascular reparative/restoration therapy — VRT). The patient was discharged home on day 4, with normal anterior 
wall thickness on echocardiogram, and only moderate anterior hypokinesia with an early left ventricular ejection fraction of 50%. 
[Procedure performed by the Author.]  
Note that while the IRA thrombus extraction by itself cannot be reasonably expected to reduce the risk of 30-day death in this 
patient (provided that any pPCI effective in IRA opening is performed), this manoeuvre removed a significant part of the throm-
botic burden that would have otherwise embolised IRA microcirculation, extending the myocardial injury (i.e. the infarct size 
— a well-established predictor of long-term STEMI outcome [1]). Randomisation of such a patient to TASTE would have been 
dependent on whether or not the operator believed that thrombus aspiration was indicated (in the latter case, TA would have 
been performed and the patient would have not contributed to the TASTE randomised cohort; if randomised to TASTE, how-
ever, this patient would have a 50% chance of a 6 F-only aspiration catheter thrombus extraction attempt). While the TASTE data 
was not centrally adjudicated, according to TASTE report [5], TA in TASTE was considered “indicated” in a minority of all-comer 
STEMI patients, suggesting that patients like this one (a ‘typical’ STEMI patient with an average thrombus burden) contributed  
to TASTE. It is unreasonable to expect that TA, in such patients, would reduce the risk of death at 30 days.  
A likely TASTE trial-represented patient with respect to TA use.
A B D C
E F G
diac embolisation with the IRA thrombotic material through 
the drag-and-drop effect [2, 3, 19]. In this respect, the TASTE 
data showing no stroke excess with TA [5, 19] is reassuring. 
It can be debated whether manual TA should be of-
fered to all STEMI patients undergoing primary PCI (i.e. 
irrespective of angiographic evidence/absence of thrombus 
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Figure 2. Coronary thrombus extraction as an essential live-saving manoeuvre in a STEMI patient. This STEMI patient is a 52-year-
-old man who was woken up by crushing retrosternal pain. ECG on paramedics’ arrival is shown in A; the patient was given oral 
aspirin (300 mg) and clopidogrel (600 mg), and unfractionated heparin (5000 IU) intravenously. While in the ambulance (trans-
port time to a primary PCI centre 40 min), the patient developed cardiogenic shock and arrested several times. He arrived directly 
to the cathlab in profound cardiogenic shock, on pharmacologic inotropic support, intubated and artificially ventilated. Coronary 
angiogram (7 F right femoral access) demonstrated non-critically diseased right coronary artery (not shown) and a thrombotic 
occlusion of the left main (LM) coronary artery (single white arrow, B and C) extending to the left anterior descending coronary 
artery (LAD, double white arrow, B and C) and the circumflex artery (Cx, double black arrow, B and C); note the low-cardiac-
-output-related contrast stagnation in the aorta in B and C. An immediate thrombus extraction was performed with a 7 F 
Export aspiration catheter from LM/LAD and from LM/Cx (D; N.B. had this first-line strategy been not sufficiently effective, the 
mother-and-child, i.e. long 6 F catheter in an 8 F guiding [2, 3], or guiding catheter direct thrombus aspiration would have been 
employed). This was a live-saving procedure that led to flow re-institution in LAD and Cx (F; the thrombi extracted are shown 
in E). Intra-aortic balloon counterpulsation was inserted via the left groin as no other means of mechanical circulatory support 
was available on site, and an intracoronary bolus of abciximab was administered and followed by an intravenous abciximab 
infusion; unfractionated heparin was supplemented. LM/Cx/LAD stenting was then performed. First, a drug-eluting stent (Xience 
3.5 × 23 mm) was implanted in the LM-Cx (stent positioning, arrows, is shown in G, the non-diseased proximal LM portion 
was deliberately not covered with the stent). Following expansion of the 1st stent, LAD was re-wired and a 2nd stent (Xience 
3.5 × 18 mm) was implanted from LAD ostium to proximal LAD, with a small, intentional, proximal protrusion to the LM (stent 
positioning in H, arrows, whereas I is the image immediately after LAD stent implantation; T-and-protrusion technique — TAP).  
Final kissing balloon inflation is shown in J, whereas K and L are the index procedure final angiographic images. The patient,  
without any neurological deficit, was discharged to a cardiac rehabilitation centre on day 6, with an overall left ventricular 
ejection fraction (LVEF) of 40%. Control coronary angiogram, performed 4 months later (M, N, O), confirmed an optimal result 
of the index procedure (optimal stents expansion with no angiographic in-stent restenosis); echocardiogram showed LVEF of 
45–50%. With the large thrombotic burden seen in B and C, it is unlikely that any reasonable operator would have included any 
similar patient in the TASTE randomised study. Note that, as something has to ‘happen’ with the thrombus during pPCI, theoreti-
cal randomisation of such a patient to no-thrombus extraction (i.e. deliberate thrombus fragmentation and IRA microcirculation 
obstruction) pPCI vs. thrombus extraction–assisted pPCI, although hard to accept ethically, could well lead to the demonstration 
of an early mortality benefit with thrombus extraction in STEMI.  
Not a trial-represented patient.  
[Index procedure by the Author and Dr Marek Andres as 2nd operator; follow-up angiogram courtesy of Dr Marek Skura, Szpital 
św. Łukasza, Tarnów].
presence [12, 13]) or whether it should be limited to those 
ACS patients whose angiogram shows evidence of thrombus 
presence [2, 26]. Recent meta-analysis of 4,514 TA patients 
in 21 randomised studies indicated a relationship between 
the magnitude of ST-segment resolution and the presence of 
thrombus at baseline angiography (p = 0.0016), indicating 
that TA (rather than applied routinely) should be used, first 
of all, when the angiogram suggests intracoronary thrombus 
presence [20]. Indeed, strategies of selective use of TA are 
becoming crystallised [2, 3, 26]. 
Another important issue is whether TA should be limited 
to those ACS that manifest with electrocardiographic (ECG) 
ST-segment elevation. It is well known, for instance, that 
angiographic evidence of the occluded culprit artery is seen 
in 20–25% of non-ST segment elevation myocardial infarc-
tion (NSTEMI) patients [27, 28]. This is particularly relevant 
for left circumflex coronary artery occlusions which may not 
manifest as ST segment elevation due to the standard ECG 
lead location (poorly reflecting the lateral wall phenomena) 
and the late depolarisation of the lateral wall [27]. The use of 
manual TA in NSTEMI is accepted by the current ESC NSTEMI 
guidelines [28] and it should be considered in NSTEMI patients 
with angiographic thrombus evidence undergoing pPCI [2, 3]. 
CONCLUSIONS 
Current 30-day mortality in STEMI, ranging from ≈3% in clini-
cal studies [1, 5, 14, 16, 29] to ≈5% in out-of-study patients 
[1, 5, 29], is low and likely to be very close to the ‘bottom’ 
of what can be achieved today with a reduction of the 
symptom-to-treatment window and timely implementation 
of the pharmaco-invasive strategy in present patient popula-
tions. Any further significant mortality reduction may not be 
feasible, due to the STEMI population and patient presentation 
factors such as, for instance, the proportion of patients with 
extensive coronary artery disease or severe pre-pPCI cardiac 
damage including cardiogenic shock, the proportion of those 
at risk of early post-hospital arrhythmic death or due to stent 
thrombosis by 30 days, or the proportion of patients with 
severe co-morbidities that affect short-term prognosis [1]. 
Therefore, manual TA (similar to any other, present or 
hypothetical, pharmacological or mechanical intervention 
in STEMI) should not be reasonably expected to be the in-
tervention powerful enough to further reduce the early (i.e. 
in-hospital or 30-day) STEMI mortality in a statistically signifi-
cant and clinically meaningful manner. The principal finding 
from TASTE (i.e. lack of effect of TA on 30-day mortality in the 
TASTE-randomised STEMI population) is thus fully expected 
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on the basis of the aggregate of data from prior randomised 
studies of TA in STEMI [13, 14, 17, 18]. Interpretation of 
this TASTE finding, however, as “evidence” for the “lack of 
effectiveness” [4–6] of thrombus aspiration is fundamentally 
wrong. Not only because no evidence (irrespective of TASTE) 
indicates that TA could affect early mortality in STEMI, but 
also because TASTE excluded from randomisation patients in 
whom TA was considered to be indicated [5]. 
In essence, the (expected) “lack of evidence” for a sig-
nificant reduction in 30-day mortality with TA in TASTE that 
excluded from randomisation patients with expected benefit 
from TA (2.8% TA vs. 3.0% no TA; p = NS) is clearly not 
“evidence for lack” of an effect of TA in STEMI patients on 
myocardial injury and infarct size reduction. Nor can it be 
taken as “evidence for lack” of a long-term effect on HF 
development or hospitalisations for HF exacerbations, or its 
potential long-term mortality benefit. Indeed, it is well known 
that a modest reduction in infarct size with TA-associated 
improved myocardial perfusion in STEMI [13–15, 17–20] 
may translate to a reduction in mortality at one–two years but 
not at 30 days [12, 14, 17, 18]. Unfortunately, the important 
patient selection bias in TASTE is likely to have an effect also 
on the long-term study outcome.
Although practicing medicine (and interventional cardi-
ology in particular) is becoming more and more the work of 
highly-skilled craftsmen, it will always remain an art of selecting 
the best available treatment strategy for a particular patient. 
While correct manual TA has a clear learning curve [30] that 
includes appropriate training and clear understanding of pro-
cedural steps [2, 3], primary PCI operators should adhere to 
current guidelines [1] and continue to provide acute myocar-
dial infarction patients with manual TA from IRA, particularly 
when the thrombus presence is evident on angiography [2, 20].
Manual TA, an adjunct to pPCI, does not “need” to 
further reduce 30-day mortality in present STEMI patients to 
“work”. Pivotal therapies in STEMI, such as aspirin or throm-
bolysis, required over 17,000 study patients to demonstrate 
mortality reduction at five weeks [32]. Current data indicates 
that by reducing myocardial injury, particularly in patients 
with a substantial thrombus burden amenable to manual 
TA [2], TA leads to evidence-based improvement in clinical 
outcomes such as reduction in HF or reduction in mortality 
at 12–24 months [12, 14, 17, 18]. 
Therefore, when it comes to the applicability of throm-
bus removal from IRA in STEMI patients today, do not get 
misled by the increasing noise of some medical headlines’ 
“tabloidism” [4, 6, 7, 31]. Publication of controversial data 
in a major journal will no doubt contribute to the journal’s 
citations, and TASTE Investigators stated that they “have been 
continuously contacted by […] two leading scientific journals 
wishing to publish” [7]. On the other hand, however, the los-
ers — due to inaccurate interpretation of biased data — may 
be your patients. 
Physicians have the right, and the duty, to evaluate the 
validity of published data. Therefore, for your STEMI and 
NSTEMI patients in 2014, stay with the guidelines in consider-
ing thrombus extraction (the guidelines, by the way, do not tell 
you what to do in every patient but help by indicating what 
one should consider in the trial-represented patients (Fig. 1) 
while a significant proportion of the all-comer population you 
treat may be not be trial-represented (Fig. 2) [2, 33]. 
Data from TASTE are neither surprising nor disappointing. 
Until (and unless) proved otherwise, the body of consistent 
evidence that TA saves myocardium which translates into 
improved long-term clinical outcomes cannot be discarded.
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